Overview

Using Oral Valacyclovir to Treat Patients With Refractory IC/BPS

Status:
Recruiting
Trial end date:
2022-04-30
Target enrollment:
0
Participant gender:
All
Summary
Interstitial cystitis/bladder pain syndrome (IC/BPS) is a collective term referring to disorders which is characterized by lower urinary tract symptoms, including bladder pain/discomfort, frequent urination without evidence of bacterial infection. The etiology of IC/BPS is still uncertain, and most current treatment for IC/BPS are only symptoms control. Our previous study revealed Epstein-Barr virus (EBV) infection presented in the IC/BPS bladders and involved the pathogenesis. Hence, using anti-viral medication valacyclovir for the patients with IC/BPS might have clinical efficacy.
Phase:
Phase 1
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Buddhist Tzu Chi General Hospital
Collaborators:
Hualien Tzu Chi General Hospital
Ministry of Science and Technology, Taiwan
Treatments:
Valacyclovir
Criteria
Inclusion Criteria:

- patients with IC/BPS

Exclusion Criteria:

- patients with neurogenic bladder

- patients with bladder outlet obstruction

- patients with lymphoma

- patients with bacteria cystitis